NewLink Genetics Corp. will give a presentation today at an international conference in Canada on research that shows a technology it's using for developing a pancreatic cancer vaccine could extend into improving infectious disease vaccines. The Ames-based biopharmaceutical company will make a presentation on its "HyperAcute alpha-gal" technology during the International Congress of Virology in Montreal. "We hope to advance a HyperAcute enhanced influenza vaccine into human clinical trials and leverage this experience by rapidly developing effective dose sparing vaccines to treat a variety of infectious diseases," said Charles Link, NewLink's chairman and CEO. NewLink's HyperAcute immunotherapy platform products are designed to stimulate the human immune system to recognize and attack cancer cells.